

# Christina Sorbe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/387329/publications.pdf>

Version: 2024-02-01

33  
papers

2,244  
citations

471509

17  
h-index

395702

33  
g-index

33  
all docs

33  
docs citations

33  
times ranked

2009  
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form. British Journal of Dermatology, 2022, 187, 588-589.	1.5	3
2	Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. British Journal of Dermatology, 2021, 184, 548-550.	1.5	4
3	A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 701-711.	2.4	13
4	Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004-2017. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1536-1542.	2.4	18
5	A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. British Journal of Dermatology, 2020, 182, 869-879.	1.5	31
6	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. British Journal of Dermatology, 2019, 181, 358-365.	1.5	42
7	Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 1100-1105.	2.6	27
8	Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatments: results from the randomized controlled PRIME trial. British Journal of Dermatology, 2017, 177, 1024-1032.	1.5	48
9	Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm <sup>®</sup> - and placebo-controlled trial (BRIDGE). British Journal of Dermatology, 2017, 176, 615-623.	1.5	111
10	European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – <sup>EDF</sup> in cooperation with <sup>EADV</sup> and <sup>IPC</sup>. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2277-2294.	2.4	353
11	German S3-guidelines on the treatment of psoriasis vulgaris (short version). Archives of Dermatological Research, 2012, 304, 87-113.	1.9	96
12	European S3-Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1-70.	2.4	683
13	Treatment targeted to cell surface epitopes. Clinical and Experimental Dermatology, 2002, 27, 591-596.	1.3	25
14	Advances in systemic therapy for psoriasis. Clinical and Experimental Dermatology, 2001, 26, 362-367.	1.3	33
15	Psoriasis scales contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells. Experimental Dermatology, 2001, 10, 238-245.	2.9	28
16	Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. British Journal of Dermatology, 1999, 141, 424-429.	1.5	193
17	Macrolide immunosuppressants. European Journal of Dermatology, 1999, 9, 346-51.	0.6	18
18	Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. British Journal of Dermatology, 1998, 138, 456-460.	1.5	214

#	ARTICLE	IF	CITATIONS
19	The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. <i>British Journal of Dermatology</i> , 1998, 139, 992-996.	1.5	103
20	Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1. <i>British Journal of Dermatology</i> , 1997, 136, 542-7.	1.5	4
21	A method for the determination of leukocyte migration for large sample numbers by automated densitometric quantification. <i>Journal of Proteomics</i> , 1995, 30, 49-58.	2.4	9
22	Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: Results of a multicenter study. <i>Journal of the American Academy of Dermatology</i> , 1995, 33, 470-475.	1.2	69
23	Infiltrating Neutrophils Differ from Circulating Neutrophils when Stimulated with C5a, NAP-I/IL-8, LTB4 and FMLP. <i>Scandinavian Journal of Immunology</i> , 1992, 35, 71-78.	2.7	6
24	Inhibition of human monocyte functions by anthralin. <i>British Journal of Dermatology</i> , 1992, 127, 382-386.	1.5	17
25	The enigma of cyclosporin A treatment for psoriasis: systemic efficacy versus topical non-responsiveness. A review. <i>Acta Dermato-Venereologica</i> , 1992, 72, 321-6.	1.3	3
26	Neutrophil-activating peptide 1/interleukin 8 mRNA expression and protein secretion by human monocytes: Effect of cyclosporin A. <i>Cytokine</i> , 1991, 3, 322-326.	3.2	13
27	Selective Inactivation of Human Neutrophil Elastase by Synthetic Tannin. <i>Journal of Investigative Dermatology</i> , 1991, 97, 529-533.	0.7	16
28	Recombinant Human Tumour Necrosis Factor beta (Lymphotoxin) Lacks Chemotactic Activity for Human Peripheral Blood Neutrophils, Monocytes, and T Cells. <i>Scandinavian Journal of Immunology</i> , 1989, 30, 373-377.	2.7	3
29	Modulation of Human Monocyte Functions during Acute Bacterial Infection. <i>Scandinavian Journal of Immunology</i> , 1988, 28, 139-146.	2.7	7
30	Atopic dermatitis: Influence of bacterial infections on human monocyte and neutrophil granulocyte functional activities. <i>Journal of Allergy and Clinical Immunology</i> , 1988, 82, 1027-1036.	2.9	11
31	Recombinant human tumor necrosis factor $\beta$ lacks chemotactic activity for human peripheral blood neutrophils and monocytes. <i>Biochemical and Biophysical Research Communications</i> , 1988, 153, 1223-1228.	2.1	37
32	Effects of cyclosporine A treatment on psoriasis. I: Influence of low-dose cyclosporine on human monocyte function in vitro. <i>Transplantation Proceedings</i> , 1988, 20, 53-7.	0.6	2
33	C5a-Specific Modulation of Phagocyte Functions in Patients with Localized Bacterial Infections. <i>Immunobiology</i> , 1987, 174, 460-472.	1.9	4